Trial Profile
A Randomized, Controlled Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective (Beta RELIEVED II)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Triamcinolone
- Indications Gouty arthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Beta-RELIEVED-II
- Sponsors Novartis
- 21 Nov 2011 Planned end date changed from 1 Aug 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov. [First extension: NCT01080131]
- 21 Nov 2011 Planned end date changed from 1 Aug 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov. [First extension: NCT01080131]
- 21 Nov 2011 Planned end date changed from 1 Aug 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov. [First extension: NCT01080131]